{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:14:40Z","timestamp":1788250480146,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Connexin-43 (Cx43), GAP-43 and actin are involved in cellular communication and cytoskeletal dynamics in gliomas, yet their clinical relevance remains largely unclear. We investigated their expression and association with survival and tumor characteristics in IDH-mutant and IDH-wildtype gliomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>134 adult patients operated for newly diagnosed gliomas WHO grades 2\u20134 in our center were included. Immunohistochemical expression of Cx43, GAP-43 and actin was assessed. Several clinical parameters, including progression-free (PFS) and overall survival (OS), were acquired from our institutional database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In IDH-wildtype tumors, higher Cx43 expression was associated with prolonged OS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.032). Whereas IDH-mutant gliomas showed significantly lower expression of Cx43 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029) compared to IDH-wildtype tumors. Actin expression correlated with prognostically unfavorable higher WHO grade (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), IDH-wildtype status (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), preoperative contrast enhancement in MRI (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009) and decreased functional status (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Consequently, stronger actin expression was significantly associated with shorter PFS (7.2 vs. 17.4 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and OS (17.1 vs. 81.5 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Incidentally diagnosed tumors exhibited reduced GAP-43 expression (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012). None of the proteins was associated with perioperative complications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Upregulated actin expression is strongly linked to more aggressive glioma behavior and reduced survival. Higher Cx43 expression could sustain an onco-protective role in prognostically unfavorable IDH-wildtype tumors. These findings provide clinically relevant translational evidence for the role of cytoskeletal and connectivity-associated proteins in glioma biology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05745-7","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T08:41:30Z","timestamp":1786178490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Actin, connexin-43 and GAP-43 expression in gliomas: real-world associations with IDH status, tumor burden and survival"],"prefix":"10.1007","volume":"179","author":[{"given":"Aleksandrs","family":"Krigers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Demetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bergmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelheid","family":"Woehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudius","family":"Thom\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian F.","family":"Freyschlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"5745_CR1","doi-asserted-by":"publisher","unstructured":"Feng J, Yang J (2025) Glioma-neuron interactions: insights from neural plasticity. Front Oncol 15. https:\/\/doi.org\/10.3389\/fonc.2025.1661897","DOI":"10.3389\/fonc.2025.1661897"},{"key":"5745_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathmechdis-051122-110348","volume":"19","author":"MA Jayaram","year":"2024","unstructured":"Jayaram MA, Phillips JJ (2024) Role of the Microenvironment in Glioma Pathogenesis. Annu Rev Pathol 19:181\u2013201. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-051122-110348","journal-title":"Annu Rev Pathol"},{"key":"5745_CR3","doi-asserted-by":"publisher","unstructured":"Sharma P, Aaroe A, Liang J, Puduvalli VK (2023) Tumor microenvironment in glioblastoma: current and emerging concepts. Neurooncol Adv 5. https:\/\/doi.org\/10.1093\/noajnl\/vdad009","DOI":"10.1093\/noajnl\/vdad009"},{"key":"5745_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41586-023-06678-1","volume":"623","author":"KR Taylor","year":"2023","unstructured":"Taylor KR, Barron T, Hui A et al (2023) Glioma synapses recruit mechanisms of adaptive plasticity. Nature 623:366\u2013374. https:\/\/doi.org\/10.1038\/s41586-023-06678-1","journal-title":"Nature"},{"key":"5745_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00441-025-04031-8","volume":"403","author":"R Kanji","year":"2026","unstructured":"Kanji R, Penuela S, Mesnil M (2026) Connexin-Pannexin duality in glioblastoma. Cell Tissue Res 403:4. https:\/\/doi.org\/10.1007\/s00441-025-04031-8","journal-title":"Cell Tissue Res"},{"key":"5745_CR6","doi-asserted-by":"publisher","unstructured":"Sinyuk M, Mulkearns-Hubert EE, Reizes O, Lathia J (2018) Cancer connectors: connexins, gap junctions, and communication. Front Oncol 8. https:\/\/doi.org\/10.3389\/fonc.2018.00646","DOI":"10.3389\/fonc.2018.00646"},{"key":"5745_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1264800","author":"M Mesnil","year":"2023","unstructured":"Mesnil M, Boyce AKJ, Wright CS (2023) Editorial: Pannexin and connexin signaling in cell death and tissue health and disease. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2023.1264800. 11:","journal-title":"Front Cell Dev Biol"},{"key":"5745_CR8","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"5745_CR9","doi-asserted-by":"publisher","unstructured":"(2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481\u20132498. https:\/\/doi.org\/10.1056\/NEJMoa1402121","DOI":"10.1056\/NEJMoa1402121"},{"key":"5745_CR10","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/s41598-023-29298-1","volume":"13","author":"A Krigers","year":"2023","unstructured":"Krigers A, Demetz M, Moser P et al (2023) Impact of GAP-43, Cx43 and actin expression on the outcome and overall survival in diffuse and anaplastic gliomas. Sci Rep 13:2024. https:\/\/doi.org\/10.1038\/s41598-023-29298-1","journal-title":"Sci Rep"},{"key":"5745_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"5745_CR12","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrc.2016.105","volume":"16","author":"T Aasen","year":"2016","unstructured":"Aasen T, Mesnil M, Naus CC et al (2016) Gap junctions and cancer: communicating for 50 years. Nat Rev Cancer 16:775\u2013788. https:\/\/doi.org\/10.1038\/nrc.2016.105","journal-title":"Nat Rev Cancer"},{"key":"5745_CR13","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/cam4.730","volume":"5","author":"S Crespin","year":"2016","unstructured":"Crespin S, Fromont G, Wager M et al (2016) Expression of a gap junction protein, connexin43, in a large panel of human gliomas: new insights. Cancer Med 5:1742\u20131752. https:\/\/doi.org\/10.1002\/cam4.730","journal-title":"Cancer Med"},{"key":"5745_CR14","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1038\/s41388-019-0741-6","volume":"38","author":"T Aasen","year":"2019","unstructured":"Aasen T, Leithe E, Graham SV et al (2019) Connexins in cancer: bridging the gap to the clinic. Oncogene 38:4429\u20134451. https:\/\/doi.org\/10.1038\/s41388-019-0741-6","journal-title":"Oncogene"},{"key":"5745_CR15","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s00432-021-03711-6","volume":"147","author":"A Krigers","year":"2021","unstructured":"Krigers A, Moser P, Fritsch H et al (2021) The advanced development of Cx43 and GAP-43 mediated intercellular networking in IDH1 wildtype diffuse and anaplastic gliomas with lower mitotic rate. J Cancer Res Clin Oncol 147:3003\u20133009. https:\/\/doi.org\/10.1007\/s00432-021-03711-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"5745_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/03936155221143138","volume":"38","author":"A Krigers","year":"2023","unstructured":"Krigers A, Moser P, Fritsch H et al (2023) The relationship between connexin-43 expression and Ki67 in non-glial central nervous system tumors. Int J Biol Markers 38:46\u201352. https:\/\/doi.org\/10.1177\/03936155221143138","journal-title":"Int J Biol Markers"},{"key":"5745_CR17","doi-asserted-by":"publisher","first-page":"7890","DOI":"10.3892\/mmr.2017.7618","volume":"16","author":"H Dong","year":"2017","unstructured":"Dong H, Zhou X-W, Wang X et al (2017) Complex role of connexin 43 in astrocytic tumors and possible promotion of glioma-associated epileptic discharge. Mol Med Rep 16:7890\u20137900. https:\/\/doi.org\/10.3892\/mmr.2017.7618","journal-title":"Mol Med Rep"},{"key":"5745_CR18","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/onc.2015.210","volume":"35","author":"WC Sin","year":"2016","unstructured":"Sin WC, Aftab Q, Bechberger JF et al (2016) Astrocytes promote glioma invasion via the gap junction protein connexin43. Oncogene 35:1504\u20131516. https:\/\/doi.org\/10.1038\/onc.2015.210","journal-title":"Oncogene"},{"key":"5745_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jnen\/nlae119","volume":"84","author":"Y Guo","year":"2025","unstructured":"Guo Y, Li Y, Su P et al (2025) Tumor microtubes: A new potential therapeutic target for high-grade gliomas. J Neuropathol Exp Neurol 84:93\u2013103. https:\/\/doi.org\/10.1093\/jnen\/nlae119","journal-title":"J Neuropathol Exp Neurol"},{"key":"5745_CR20","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s43018-023-00556-5","volume":"4","author":"DC Watson","year":"2023","unstructured":"Watson DC, Bayik D, Storevik S et al (2023) GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity. Nat Cancer 4:648\u2013664. https:\/\/doi.org\/10.1038\/s43018-023-00556-5","journal-title":"Nat Cancer"},{"key":"5745_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/neuonc\/now014","volume":"18","author":"M Osswald","year":"2016","unstructured":"Osswald M, Solecki G, Wick W, Winkler F (2016) A malignant cellular network in gliomas: potential clinical implications. Neuro Oncol 18:479\u2013485. https:\/\/doi.org\/10.1093\/neuonc\/now014","journal-title":"Neuro Oncol"},{"key":"5745_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ebiom.2017.06.020","volume":"21","author":"P Schiapparelli","year":"2017","unstructured":"Schiapparelli P, Guerrero-Cazares H, Maga\u00f1a-Maldonado R et al (2017) NKCC1 Regulates Migration Ability of Glioblastoma Cells by Modulation of Actin Dynamics and Interacting with Cofilin. EBioMedicine 21:94\u2013103. https:\/\/doi.org\/10.1016\/j.ebiom.2017.06.020","journal-title":"EBioMedicine"},{"key":"5745_CR23","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1158\/0008-5472.CAN-13-3426","volume":"75","author":"SY Wong","year":"2015","unstructured":"Wong SY, Ulrich TA, Deleyrolle LP et al (2015) Constitutive Activation of Myosin-Dependent Contractility Sensitizes Glioma Tumor-Initiating Cells to Mechanical Inputs and Reduces Tissue Invasion. Cancer Res 75:1113\u20131122. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3426","journal-title":"Cancer Res"},{"key":"5745_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41419-018-0548-3","volume":"9","author":"J Ji","year":"2018","unstructured":"Ji J, Xu R, Zhang X et al (2018) Actin like-6A promotes glioma progression through stabilization of transcriptional regulators YAP\/TAZ. Cell Death Dis 9:517. https:\/\/doi.org\/10.1038\/s41419-018-0548-3","journal-title":"Cell Death Dis"},{"key":"5745_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"key":"5745_CR26","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, van den Bent M, Tonn JC et al (2017) European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18:e315\u2013e329. https:\/\/doi.org\/10.1016\/S1470-2045(17)30194-8","journal-title":"Lancet Oncol"},{"key":"5745_CR27","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G et al (2023) RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 41:5187\u20135199. https:\/\/doi.org\/10.1200\/JCO.23.01059","journal-title":"J Clin Oncol"},{"key":"5745_CR28","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/1097-0142(19840501)53:9<2002::aid-cncr2820530933>3.0.co;2-w","volume":"53","author":"V Mor","year":"1984","unstructured":"Mor V, Laliberte L, Morris JN, Wiemann M (1984) The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 53:2002\u20132007. https:\/\/doi.org\/10.1002\/1097-0142(19840501)53:9%25;3C2002::aid-cncr2820530933%25;3E3.0.co;2-w","journal-title":"Cancer"},{"key":"5745_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11060-022-04001-y","volume":"158","author":"J Klingenschmid","year":"2022","unstructured":"Klingenschmid J, Krigers A, Pinggera D et al (2022) The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma. J Neurooncol 158:15\u201322. https:\/\/doi.org\/10.1007\/s11060-022-04001-y","journal-title":"J Neurooncol"},{"key":"5745_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"5745_CR31","doi-asserted-by":"publisher","unstructured":"Cerver\u00f3-Garc\u00eda P, Jim\u00e9nez-Madrona E, \u00c1lvarez-V\u00e1zquez A et al (2026) The Src inhibitor peptide TAT-Cx43266-283 improves survival in an intracranial murine model of lung cancer brain metastasis. Neurooncol Adv 8. https:\/\/doi.org\/10.1093\/noajnl\/vdag001","DOI":"10.1093\/noajnl\/vdag001"},{"key":"5745_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/neuonc\/noz243","volume":"22","author":"M Jara\u00edz-Rodr\u00edguez","year":"2020","unstructured":"Jara\u00edz-Rodr\u00edguez M, Talaver\u00f3n R, Garc\u00eda-Vicente L et al (2020) Connexin43 peptide, TAT-Cx43266\u2013283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo. Neuro Oncol 22:493\u2013504. https:\/\/doi.org\/10.1093\/neuonc\/noz243","journal-title":"Neuro Oncol"},{"key":"5745_CR33","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/neuonc\/noae060","volume":"26","author":"A \u00c1lvarez-V\u00e1zquez","year":"2024","unstructured":"\u00c1lvarez-V\u00e1zquez A, San-Segundo L, Cerver\u00f3-Garc\u00eda P et al (2024) EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266\u2013283 antitumor response in preclinical glioblastoma models. Neuro Oncol 26:1230\u20131246. https:\/\/doi.org\/10.1093\/neuonc\/noae060","journal-title":"Neuro Oncol"},{"key":"5745_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.coph.2018.05.002","volume":"41","author":"CL Grek","year":"2018","unstructured":"Grek CL, Sheng Z, Naus CC et al (2018) Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. Curr Opin Pharmacol 41:79\u201388. https:\/\/doi.org\/10.1016\/j.coph.2018.05.002","journal-title":"Curr Opin Pharmacol"},{"key":"5745_CR35","first-page":"4296","volume":"8","author":"X-Y Ye","year":"2015","unstructured":"Ye X-Y, Jiang Q-H, Hong T et al (2015) Altered expression of connexin43 and phosphorylation connexin43 in glioma tumors. Int J Clin Exp Pathol 8:4296\u20134306","journal-title":"Int J Clin Exp Pathol"},{"key":"5745_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40336-022-00489-6","volume":"10","author":"A Pellerino","year":"2022","unstructured":"Pellerino A, Caccese M, Padovan M et al (2022) Epidemiology, risk factors, and prognostic factors of gliomas. Clin Transl Imaging 10:467\u2013475. https:\/\/doi.org\/10.1007\/s40336-022-00489-6","journal-title":"Clin Transl Imaging"},{"key":"5745_CR37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s11060-023-04301-x","volume":"162","author":"M Demetz","year":"2023","unstructured":"Demetz M, Krigers A, Moser P et al (2023) Same but different. Incidental and symptomatic lower grade gliomas show differences in molecular features and survival. J Neurooncol 162:397\u2013405. https:\/\/doi.org\/10.1007\/s11060-023-04301-x","journal-title":"J Neurooncol"},{"key":"5745_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00701-025-06594-5","volume":"167","author":"M Demetz","year":"2025","unstructured":"Demetz M, Krigers A, Klingenschmid J et al (2025) Socioeconomic influences on survival outcome in idh-wildtype glioma patients: examining the role of age, education, and lifestyle factors. Acta Neurochir (Wien) 167:178. https:\/\/doi.org\/10.1007\/s00701-025-06594-5","journal-title":"Acta Neurochir (Wien)"},{"key":"5745_CR39","doi-asserted-by":"publisher","first-page":"217114","DOI":"10.1016\/j.canlet.2024.217114","volume":"598","author":"J Yin","year":"2024","unstructured":"Yin J, Liu G, Zhang Y et al (2024) Gender differences in gliomas: From epidemiological trends to changes at the hormonal and molecular levels. Cancer Lett 598:217114. https:\/\/doi.org\/10.1016\/j.canlet.2024.217114","journal-title":"Cancer Lett"},{"key":"5745_CR40","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.3390\/cancers17213584","volume":"17","author":"M Demetz","year":"2025","unstructured":"Demetz M, Krigers A, Miller-Michlits A et al (2025) Multiple Primaries: Differences in Survival of Patients with Glioma with or Without Second Malignancies. Cancers (Basel) 17:3584. https:\/\/doi.org\/10.3390\/cancers17213584","journal-title":"Cancers (Basel)"},{"key":"5745_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/pro.3307","volume":"27","author":"PJ Thul","year":"2018","unstructured":"Thul PJ, Lindskog C (2018) The human protein atlas: A spatial map of the human proteome. Protein Sci 27:233\u2013244. https:\/\/doi.org\/10.1002\/pro.3307","journal-title":"Protein Sci"},{"key":"5745_CR42","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1074\/jbc.M112.386722","volume":"288","author":"S Shimamura","year":"2013","unstructured":"Shimamura S, Sasaki K, Tanaka M (2013) The Src substrate SKAP2 regulates actin assembly by interacting with WAVE2 and cortactin proteins. J Biol Chem 288:1171\u20131183. https:\/\/doi.org\/10.1074\/jbc.M112.386722","journal-title":"J Biol Chem"},{"key":"5745_CR43","doi-asserted-by":"publisher","first-page":"13352","DOI":"10.1038\/s41598-020-70392-5","volume":"10","author":"NG Avci","year":"2020","unstructured":"Avci NG, Ebrahimzadeh-Pustchi S, Akay YM et al (2020) NF-\u03baB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-\u03baB(p65) and actin cytoskeleton regulatory pathways. Sci Rep 10:13352. https:\/\/doi.org\/10.1038\/s41598-020-70392-5","journal-title":"Sci Rep"},{"key":"5745_CR44","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1038\/s41388-018-0546-z","volume":"38","author":"JP Zepecki","year":"2019","unstructured":"Zepecki JP, Snyder KM, Moreno MM et al (2019) Regulation of human glioma cell migration, tumor growth, and stemness gene expression using a Lck targeted inhibitor. Oncogene 38:1734\u20131750. https:\/\/doi.org\/10.1038\/s41388-018-0546-z","journal-title":"Oncogene"},{"key":"5745_CR45","doi-asserted-by":"crossref","unstructured":"Kwiatkowska A, Symons M (2020) Signaling determinants of glioma cell invasion. pp 129\u2013149","DOI":"10.1007\/978-3-030-30651-9_7"},{"key":"5745_CR46","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3171\/2016.1.JNS152075","volume":"126","author":"S Ohtaki","year":"2017","unstructured":"Ohtaki S, Wanibuchi M, Kataoka-Sasaki Y et al (2017) ACTC1 as an invasion and prognosis marker in glioma. J Neurosurg 126:467\u2013475. https:\/\/doi.org\/10.3171\/2016.1.JNS152075","journal-title":"J Neurosurg"},{"key":"5745_CR47","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/neuonc\/nox070","volume":"19","author":"S Weil","year":"2017","unstructured":"Weil S, Osswald M, Solecki G et al (2017) Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas. Neuro Oncol 19:1316\u20131326. https:\/\/doi.org\/10.1093\/neuonc\/nox070","journal-title":"Neuro Oncol"},{"key":"5745_CR48","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1878-0261.13786","volume":"19","author":"ENC Schmidt","year":"2025","unstructured":"Schmidt ENC, Evert BO, Pregler BEF et al (2025) Tonabersat enhances temozolomide-mediated cytotoxicity in glioblastoma by disrupting intercellular connectivity through connexin 43 inhibition. Mol Oncol 19:878\u2013898. https:\/\/doi.org\/10.1002\/1878-0261.13786","journal-title":"Mol Oncol"},{"key":"5745_CR49","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3390\/cancers11060858","volume":"11","author":"A-L Potthoff","year":"2019","unstructured":"Potthoff A-L, Heiland DH, Evert BO et al (2019) Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide. Cancers (Basel) 11:858. https:\/\/doi.org\/10.3390\/cancers11060858","journal-title":"Cancers (Basel)"},{"key":"5745_CR50","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/neuonc\/noab210","volume":"24","author":"T Ius","year":"2022","unstructured":"Ius T, Ng S, Young JS et al (2022) The benefit of early surgery on overall survival in incidental low-grade glioma patients: A multicenter study. Neuro Oncol 24:624\u2013638. https:\/\/doi.org\/10.1093\/neuonc\/noab210","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05745-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05745-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05745-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:27:20Z","timestamp":1788247640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05745-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5745"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05745-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"36"}}